Biogen Inc.

NASDAQ:BIIB

Drug Manufacturers - General

Healthcare
$251.41 -1.11%

-$2.21 today

Market cap
$37.16B
Beta
0.18
P/E (TTM)
21.1
EPS (TTM)
$9.32
52W Low $121.05High $205.97

Volume 1.14M

Average 1.17M

BIIB Other Current Assets

Current assets not reported separately, such as prepaid expenses.

Biogen Inc.NASDAQ: BIIB

Other Current Assets · Q2 FY2026 · quarter ended Jun 2026

Other current assets rises 105.8% from a year ago

Other current assets stood at $1.75B at the end of Q2 FY2026, up 105.8% from a year earlier and up 49.9% from the prior quarter. Over 3 fiscal years it compounded at -7.5% a year.

Context

  • Other current assets amounted to 5.5% of total assets at the end of Q2 FY2026, up 2.5 pp from a year earlier.
  • Other current assets increased in 1 of the last 3 fiscal years.

What to watch

Whether other current assets keeps rising in the next quarterly balance sheet after a +105.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$1.75B+49.9% QoQ
Last fiscal yearDec 2025
$1.12B+49.3% YoY
Year agoJun 2025
$850.6M+105.8% since
Other Current Assets past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+105.8%——
1 year+49.3%——
3-year CAGR-7.5%——
5-year CAGR——
10-year CAGR——

Other Current Assets history

USD · from the balance sheet

Latest · FY2025
1.12B USD
Year-over-year change
+49.3%
4-year CAGR
+11.0%

Other Current Assets vs competitors

How BIIB compares with its peers on the latest reported figures

  • BIIB's Jun 2026 other current assets of $1.75B is the 3rd highest of the 11 companies compared; the peer median is $309.74M.
  • Its year-over-year change of +105.8% is the 2nd highest of 11, against a peer median of +28.6%.
  • Other current assets amounts to 5.5% of total assets for BIIB, versus a peer median of 3.1%.
BIIB Competitors Peer median
Other Current Assets for BIIB and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
PFEPfizer Inc.Jun 2026$7.22B +168.5%-17.6%3.6%
AMGNAmgen Inc.Jun 2026$4.53B +32.2%+126.6%4.7%
BIIBBiogen Inc.Jun 2026$1.75B +105.8%-7.5%5.5%
VRTXVertex Pharmaceuticals IncorporatedSep 2026$826.7M +16.5%+83.1%2.5%
IONSIonis Pharmaceuticals, Inc.Sep 2026$360.68M +48.1%+16.1%12.4%
UTHRUnited Therapeutics CorporationJun 2026$317.3M +38.1%+94.5%4.4%
ALNYAlnylam Pharmaceuticals, Inc.Jun 2026$302.18M +105.1%+28.5%5.4%
LLYEli Lilly and CompanyJun 2026$86M +25.0%+172.1%0.1%
PTCTPTC Therapeutics, Inc.Jun 2026$57.88M +8.1%-14.0%1.8%
AZNAstraZeneca PLCSep 2026$19.97M -97.6%+3.4%0.0%
REGNRegeneron Pharmaceuticals, Inc.Jun 2026$0 -100.0%—0.0%
Peer median (excluding BIIB) $309.74M+28.6%+28.5%3.1%

Competitors are the stored peer set for BIIB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents2.26B3.42B1.05B2.38B3.01B
Short-term Investments1.54B1.47B00807.2M
Net Receivables1.96B2.14B2.1B1.87B1.87B
Inventory1.35B1.34B2.53B2.46B2.17B
Other Current Assets740.8M1.42B1.18B752.5M1.12B
Total Current Assets7.86B9.79B6.86B7.46B8.97B
Property, Plant & Equipment (Net)3.79B3.7B3.73B3.54B3.32B
Goodwill5.76B5.75B6.22B6.48B6.49B
Intangible Assets2.22B1.85B8.36B9.69B9.18B
Long-term Investments892M705.7M460.7M226.7M750.6M
Tax Assets1.42B1.23B928.6M324.2M292.5M
Other Non-current Assets1.94B1.53B284.3M333.8M431.9M
Total Non-current Assets16.02B14.76B19.99B20.59B20.47B
Total Assets23.88B24.55B26.84B28.05B29.44B
Account Payables589.2M491.5M403.3M424.2M432M
Short-term Debt999.1M0150M1.75B80.4M
Tax Payables174.7M259.9M257.4M548.3M114.8M
Deferred Revenue00000
Other Current Liabilities345.1M1.14B335.1M375.8M2.72B
Total Current Liabilities4.3B3.27B3.43B5.53B3.35B
Long-term Debt6.27B6.28B6.79B4.55B6.58B
Deferred Tax Liabilities694.5M334.7M641.8M190.5M507.6M
Deferred Revenue (Non-current)00000
Other Non-current Liabilities1.32B944.2M781.1M732.3M458.1M
Total Non-current Liabilities8.62B7.89B8.61B5.8B7.83B
Total Liabilities12.92B11.17B12.05B11.33B11.18B
Common Stock100K100K100K100K100K
Retained Earnings13.91B16.47B17.63B19.26B20.55B
Accumulated OCI(106.7M)(164.9M)(153.7M)(136.2M)(182M)
Other Stockholders Equity00000
Minority Interest63.5M(9.5M)000
Total Equity10.96B13.39B14.8B16.72B18.26B
Total Debt7.6B6.61B7.34B6.63B6.95B
Net Debt5.34B3.19B6.29B4.26B3.94B

Biogen Inc.

NASDAQ:BIIB

Intrinsic Alpha fair value

Locked

Current Price

$251.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.